Regulation of phosphorylation of Deoxycytidine and 2′,2′-Difluorodeoxycytidine (Gemcitabine); effects of Cytidine 5′-Triphosphate and Uridine 5′-Triphosphate in Relation to Chemosensitivity for 2′,2′-Difluorodeoxycytidine

Biochemical Pharmacology

Volumn 51, Issue 7, 1996, Pages 911-918

  Ruiz Van Haperen, Veronique W T ^a,b   Veerman, Gijsbert ^b   Vermorken, Jan B ^b   Pinedo, Herbert M ^b   Peters, Godefridus J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CTP; Deoxycytidine deaminase; Deoxycytidine kinase; Deoxynucleosides; Gemcitabine; Pyrimidine salvage; Regulation; UTP

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE; DEOXYCYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DRUG METABOLITE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; RADIOISOTOPE; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REGULATORY MECHANISM; SOLID TUMOR;

CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; NUCLEOSIDE DEAMINASES; OVARIAN NEOPLASMS; PHOSPHORYLATION; TUMOR CELLS, CULTURED; URIDINE TRIPHOSPHATE;

EID: 0029990087     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02402-6     Document Type: Article

References (33)

1. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B and Johansson NG, Comparison of the substrate specificity of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Comm 176: 586-592, 1991.
2. Heinemann V, Hertel LW, Grindey GB and Plunkett W, Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031, 1988.
3. Ruiz van Haperen VWT and Peters GJ, New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2. Deoxycytidine kinase. Pharm World Sci 16: 104-112, 1994.
4. Chabner BA, Johns DG, Coleman CN, Drake JC and Evans WH, Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest 53: 922-931, 1974.
5. Heinemann V, Hertel LW, Grindey GB and Plunkett W, Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031, 1988.
6. Ho DHW, Distribution of kinase and deaminase of 1-βD-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 33: 2816-2820, 1973.
7. Hagenbeek A, Martens ACM and Colly LP, In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia. Semin Oncol 14: 202-206, 1987.
8. Stueart CD and Burke PJ, Cytidine deaminase and the development of resistance to cytosine arabinoside. Nature (New Biology) 233: 109, 1971.
9. Grant S, Biochemical modulation of cytosine arabinoside. Pharmacol Ther 48: 29-44, 1990.
10. Shewach DS, Reynolds KK and Hertel LW, Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 42: 518-524, 1992.
11. White JC and Hines LH, Role of uridine triphosphate in the phosphorylation of 1-β-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells. Cancer Res 47: 1820-1824, 1987.
12. Durham JP and Ives DH, Deoxycytidine kinase II Purification and general properties of the calf thymus enzyme. J Biol Chem 245: 2276-2284, 1970.
13. Sarup JC, Johnson MA, Verhoeff V and Fridland A, Regulation of purine deoxynucleoside phosphorylation by deoxycytidine kinase from human leukemic blast cells. Biochem Pharmacol 38: 2601-2607, 1989.
14. Ruiz van Haperen VWT, Veerman G, Braakhuis BJM, Vermorken JB, Boven E, Leyva A and Peters GJ, Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 29A: 2132-2137, 1993.
15. Spasokoukotskaja T, Arnér ESJ, Brosjö O, Gunvén P, Juliusson G, Liliemark J and Eriksson S, Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumor cells and tissues. Eur J Cancer 31A: 202-208, 1995.
16. Lund B, Kristjansen PEG and Hansen H, Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treatm Rev 19: 45-55, 1993.
17. Kaye SB, Gemcitabine: current status of phase I and phase II trials. J Clin Oncol 12: 1527-1531, 1994.
18. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA, Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540, 1994.
19. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W, Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
20. Ruiz van Haperen VWT, Veerman G, Vermorken JB and Peters GJ, 2′,2′,-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46: 762-766, 1993.
21. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB and Peters GJ, Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 48: 1327-1339, 1994.
22. Peters GJ, Kraal I and Pinedo HM, In vitro and in vivo studies on the combination of brequinar sodium (DUP 785, NSC 368390) with 5-fluorouracil; effects of uridine. Br J Cancer 65: 229-233, 1992.
23. Bradford M, A rapid and sensitive method for the qualification of microgram quantities of protein using the principle of protein-dye binding. Analyt Biochem 72: 248-254, 1976.
24. Ruiz van Haperen VWT, Veerman G, Eriksson S, Boven E, Stegmann APA, Hermsen M, Vermorken JB, Pinedo HM and Peters GJ, Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54: 4138-4143, 1994.
25. Bohman C and Eriksson S, Deoxycytidine kinase from human leukemic spleen: preparation and characteristics of homogenous enzyme. Biochemistry 27: 4258-4265, 1988.
26. Datta NS, Shewach DS, Hurley MC, Mitchell BS and Fox IH, Human T-lymphoblast deoxycytidine kinase: purification and properties. Biochemistry 28: 114-123, 1989.
27. Singhal RL, Yeh YA, Scekeres T and Weber G, Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine. Oncol Res 4: 517-522, 1992.
28. Stegmann APA, Honders MW, Rester MGD, Landegent JE and Willemze R1 Role of deoxycytidine kinase in an in vitro model for ara-C and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-β-D-arabinosylcytosine and substrate-enzyme interactions with deoxycytidine, 1-β-D-arabinosylcytosine and 5-aza-2′-deoxycytidine. Leukemia 7: 1005-1011, 1993.
29. Shewach DS, Reynolds KK and Hahn T, Apparent allosteric regulation of deoxycytidine kinase by UTP. Proc Am Assoc Cancer Res 34: 10, 1993.
30. Habteyesus A, Nordenskjöld A, Bohman C and Eriksson S, Deoxynucleoside phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specificity. Biochem Pharmacol 42: 1829-1836, 1991.
31. Grant S, Rauscher F III, and Cadman E, Differential effect of N-(phosphonacetyl)-L-aspartate on 1-β-D-Arabinofuranosyl-cytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors. Cancer Res 42: 4007-4013, 1982.
32. Plunkett W, Adams T and Keating M, Modulation of Ara-CTP metabolism in leukemia cells during high-dose Ara-C (HD Ara-C) therapy by thymidine and PALA. Proc Am Assoc Clin Oncol 6: 30 (abstract), 1987.
33. Noordhuis P, Kazemier KM, Kaspers GJL and Peters GJ, Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Leukemia Res, in press.